2-DAY ORAL DESENSITIZATION TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN HIV-INFECTED PATIENTS

Objective: To establish whether an outpatient, 2-day oral desensitizat ion protocol would be both sale and effective in HIV-infected patients with previous trimethoprim-sulfamethoxazole (TMP-SMX) intolerance. De sign: A single center trial of TMP-SMX desensitization in HIV-infected patients with prior TMP-SMX hypersensitivity reactions. Methods: HIV- infected patients with CD4 lymphocyte counts <250x10(6)/I cells or CD4 %<20% with previous non-life-threatening hypersensitivity reactions to TMP-SMX were eligible. The desensitization protocol utilized 40 gradu ated doses over 36 h; the first 28 doses (7.5 h) of the protocol were given in an outpatient clinic with the remaining doses taken at home. Results: Twenty-seven (60%) of the 45 subjects completed the protocol and were subsequently maintained on daily TMP-SMX without adverse reac tions (mean follow-up, 9 months; range, 4-16 months). Patients with CD 4 counts <100x10(6)/I cells were just as likely as patients with highe r CD4 counts to tolerate the desensitization. No patient required hosp italization for treatment of an adverse reaction. Conclusion: Oral des ensitization to TMP-SMX in HIV-infected patients is a useful option in the management of patients with advanced HIV disease and prior intole rance to TMP-SMX.